FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Jan 15, 2src25 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that...
